Onco Actu du 14 octobre 2015

	2. Etiologie
Am I more likely to get cancer because I'm tall? [BBC News] Tim Cole, a professor of medical statistics at University College London, says there's no need for tall people to worry - especially as increased height normally means you're less likely to get other conditions, such as heart disease. "Being taller suggests you've had a better experience, a more healthy experience in childhood," he says.
	3.1 Tabac
Fresh Empire: FDA launches an Innovative Tobacco Public Education Campaign [FDA Voice] The aim of the campaign is to associate living tobacco-free with desirable hip-hop lifestyles through a variety of interactive marketing tactics including the use of traditional paid media, engagement through multiple digital platforms, and outreach at the local level.
	5.12 Immunothérapies
It Takes Two to Tango: Combining Epigenetic Therapy and Immunotherapy [CANCER RESEARCH Catalyst] In their paper, Maio and colleagues discuss the rationale behind combining epigenetic therapies with immunotherapies such as interleukin-2 therapy, adoptive T-cell transfer, and immune checkpoint inhibitors, among others.
	5.2 Pharma
Artificial Intelligence, You Say? [In the Pipeline] Their approach is ambitious, although certainly not crazy, but they’re going to want to keep an eye on their press coverage. Talking up “artificial intelligence” and “cutting development times in half” may bring them a bit more notoriety than is needed.
	5.2.1 Pharma - Partenariats
Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration [Lilly] Per the agreement, ImaginAb will conduct preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules.
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma [Merck] Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with advanced or metastatic melanoma.
	5.2.3 Pharma - économie
Pfizer's CEO Faces The Drug Pricing Firestorm [Forbes] A bigger question is whether Ibrance is too expensive. It costs $118,000 per patient per year, and other cancer drugs, like Merck’s Keytruda and Amgen’s Blincyto, cost more. One drug combination from Bristol-Myers Squibb for melanoma can cost $256,000 per patient. “I understand the physicians saying, ‘Look, these prices are too high,’ ” Read says. “ It’s because their patients can’t get access. That is an insurance issue.”
	5.3 Traitements - FDA, EMA,...
NICE launches initiative to speed up adoption of health technologies [NICE] NICE is introducing a new service, the Office for Market Access (OMA), an initiative to work with industry to speed up adoption of new medicines, devices and diagnostics by the NHS.
	5.4 Traitements - Economie
Is This Cancer Treatment Worth It? New Tool Offers Patients Data [Bloomberg] For the first time, a consortium of top U.S. cancer hospitals will provide patients with guidance about the cost of drugs used in their treatment, helping address a concern for many people undergoing a major medical event -- what the financial repercussions of their condition are.
Four Reasons Drugs Are Expensive, Of Which Two Are False [Forbes] When Jack Scannell, the guy who coined the term “Eroom’s Law” (Moore’s Law backwards) to describe the exponential increase in the cost of developing a new drug between 1950 and 2010, tells you he wants to tell you everything he thinks about drug prices, you listen.
	6. Lutte contre les cancers
Human Longevity, Inc. Launches the Health Nucleus, a Comprehensive and Personalized Health Platform for Individuals [Human Longevity, Inc.] The Health Nucleus platform uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning – combined with a comprehensive curation of personal health history – to deliver the most complete picture of individual health.
ASCO Introduces New Online Genetics Toolkit [ASCO] The Genetics Toolkit offers a wide range of resources, including information on the characteristics of hereditary cancer risk, assessing a patients’ hereditary risk, understanding panel tests and genetic testing results, using risk assessment models, and other aspects of incorporating clinical cancer genetics into cancer treatment and management plans.
Does lack of physical exercise jeopardise a patient's chances of survival? [Cancer World] Exercise reduces the risks of getting some cancers – but what about after diagnosis? What should we be advising our patients?
	6.1 Observation
Lack of referrals for suspected cancer leads to more deaths (Cancer Research UK] Death rates increased by seven per cent in patients from practices which used the two-week urgent referral route least often compared with practices with a typical referral rate.
Disparities in Breast Cancer Persist Across All Subtypes and Stages [AACR] African-American Women Are More Likely to Develop Aggressive Types and Receive Substandard Care.
Thousands of cancer patients die needlessly due to referral delays [The Guardian] Published in the British Medical Journal (BMJ), the study, which was funded by Cancer Research UK and National Institute for Health Research, examined data from 215,284 English cancer patients in 2009.
Thousands of cancer patients dying because GPs fail to refer for tests [The Telegraph] Almost 2,500 people might still be alive if family doctors had used a two week urgent referral pathway, a key part of the strategy to cut deaths in England, Kings College London has calculated.
Cancer survivors often have poor diets [Reuters] Researchers analyzed the diets of about 1,500 cancer survivors and 3,000 people without any history of tumors, ranking them based on how well they followed U.S. dietary recommendations.
	6.7 DMP, Big Data & applis
The Inevitability of Healthcare IT Interoperability: What We Learned From October 6th [The OBR Blog] As our understanding of this whirlwind of information takes shape, we are encouraged to see that the one thing that will truly move the needle on interoperability will now be a requirement in Stage 3: application program interfaces (APIs).
	6.9 Controverses
Most animal research studies may not avoid key biases [Science] Researchers who conduct animal studies often don't use simple safeguards against biases that have become standard in human clinical trials—or at least they don't report doing so in their scientific papers, making it impossible for readers to ascertain the quality of the work, an analysis of more than 2500 journal articles shows.
Much of preclinical research into one cancer drug is flawed, says report [Retraction Watch] The research focused on reports of 158 experiments, which tested the effects of sunitinib using 2716 animals.